🌐In this nationwide cohort from Sweden, both histologic inflammation (vs. histologic remission) and clinically active IBD (vs. quiescent IBD) were associated with an increased 2-year mortality risk in patients with IBD. @jiangwei_sun; @ludvigsson 🔗: https://ow.ly/QijX50YVzgj

People with MASLD and advanced fibrosis have a substantial risk of hepatocellular carcinoma in this IPD meta-analysis. Findings may inform future risk‑stratification strategies. 🧬📊 @DrHuangDQ @LimRyan21 🔗: https://ow.ly/rZKm50YVyPI

🚨Placebo response rates are often high in patients with MASH, but vary by the outcome measured. This study offers critical insights to improve future clinical trial design. 🔗: https://ow.ly/MymC50YVyEu

Happening soon! Join us at AGA Central for You’ve Published Your Paper… Now What? and learn strategies for promoting your work from our @AGA_GHA & @AGA_CGH social media editors Nikki Duong MD and Joseph Sleiman, MD #DDW2026 📅 5/4 | ⏰ 2 PM CT | 📍 AGA Central

Join us bright and early at AGA Central for our One Paper, Zero Confusion session — get tips on getting your title and graphical abstract just right from @AGA_CMGH editors-in-chief Michele Battle & Jonathan Katz! #DDW2026 📅 5/4 | ⏰ 8 AM CT | 📍 AGA Central

Happening today! Don’t miss our From Poster to Submission session at AGA Central with the editors-in-chief of @AGA_Gastro, @AGA_CGH, and @AGA_CMGH! #DDW2026 📅 5/2 | ⏰ 1 PM CT | 📍 AGA Central

Already published at #DDW2026? Join us at AGA Central for You’ve Published Your Paper… Now What? and learn what comes next. Featuring our @AGA_GHA & @AGA_CGH social media editors Nikki Duong MD and Joseph Sleiman, MD#DDW2026? 📅 5/4 | ⏰ 2 PM CT | 📍 AGA Central

Mapping out your #DDW2026 schedule? Join us at AGA Central for One Paper, Zero Confusion—tips on getting your title and graphical abstract just right with @AGA_CMGH editors-in-chief Michele Battle & Jonathan Katz! 📅 5/4 | ⏰ 8 AM CT | 📍 AGA Central

Attending #DDW2026? Stop by AGA Central for our From Poster to Submission session! Featuring editors-in-chief of @AGA_Gastro, @AGA_CGH, and @AGA_CMGH. 📅 5/2 | ⏰ 1 PM CT | 📍 AGA Central

📖 In case you missed it, the May 2026 issue of CGH is out! Featured topics ⬇️ 🟢 Esophageal inflammatory diseases 🟢 Extended risankizumab treatment in UC 🟢 CRC screening interventions ➡️ Full issue: https://ow.ly/9shw50YRMt5

There's still time! The AGA Journals are accepting applications for a one-year editorial fellowship focused on editorial training and leadership development. ⭐Perfect for early-career GIs and PhDs ✅Applications due April 30, 11:50 p.m. EST 👩‍⚕️Learn more: https://ow.ly/u7Gq50YOFoY

💊GLP-1 drugs like Ozempic and Wegovy have far-reaching health benefits beyond weight loss. In a new nationwide cohort study, researchers from Beth Israel Deaconess Medical Center are adding one more to that list: prevention of ulcers in the gut. 🔗: https://ow.ly/u2Oa50YO61B

🌟This international, multicenter study identified both commonalities and unique differences in disease phenotype and behavior by geography and immigrant status, highlighting the impact of changing environment on CD phenotypic expression. 🔗: https://ow.ly/A8uK50YLl9u

Subcutaneous infliximab (infliximab‑dyyb SC) maintenance improved outcomes in Crohn’s disease regardless of location, showing consistent efficacy across ileocolonic segments—including the terminal ileum. 💉✨ 🔗: https://ow.ly/PuPX50YFESt

🥗 Do dietary emulsifiers affect gut health? In a randomized trial, an emulsifier‑free diet lowered cholesterol, while common emulsifiers reduced short‑chain fatty acids and increased gut permeability in some participants. 🧫🦠 🔗: https://ow.ly/pVeC50YFEq4

📈 DGBI prevalence and burden increased in the UK & US after COVID-19. Key factors include repeat infections, abdominal pain/diarrhea during infection, and long COVID. 🦠🧠 🔗: https://ow.ly/gQCL50YFE4t

💊GLP-1 drugs like Ozempic and Wegovy have far-reaching health benefits beyond weight loss. In a new nationwide cohort study, researchers from Beth Israel Deaconess Medical Center are adding one more to that list: Prevention of ulcers in the gut! 🔗: https://ow.ly/FSJ450YBJUt

🧪 Plastic exposure is unavoidable. As plastics break down into micro‑ and nanoplastics, they spread through water, soil, and air—and when ingested, may disrupt gut microbes and mucosal barriers, driving inflammatory and carcinogenic effects. ⚠️🦠 🔗: https://ow.ly/xrHv50YBJuM

📊 New multicenter data show peripancreatic vascular involvement is common in autoimmune pancreatitis—and highly responsive to glucocorticoids. Monitoring can help prevent life‑threatening gastric varices. 💊🩸 🔗: https://ow.ly/tfp050YBJiH

📊 Real‑world TORUS study: after anti‑TNF failure in UC, tofacitinib and ustekinumab showed similar effectiveness. Tofacitinib may be favored after multiple biologic failures or primary biologic nonresponse. 🔍✅ Read More: https://ow.ly/Fhfc50YyRGx

🧪 In this Phase 2a study in Asian patients with MASLD: the THR‑β agonist HSK31679 significantly reduced liver fat content after 12 weeks—greatest with 80 mg and 160 mg. ✅ The treatment was well tolerated, with no AE‑related discontinuations. Read More: https://ow.ly/LBj550YyRpx

🧬 Who should be treated for MASLD? This Hepatology original research article explores a practical criteria set—combining FIB‑4, transient elastography, diabetes, and overweight status—to better guide treatment decisions. 📖✨ Read More: https://ow.ly/Khfe50YyR2o

🌍 April 2026 Editors Essential Reading 📘 This Global NASH/MASH Council study projects that by 2040, the clinical, economic, and humanistic burden of MASH will more than double worldwide—underscoring the urgent need for action. 🚨 Read More: https://ow.ly/f8yR50YyQrU

🗣️ The newest issue of CGH is here!! ➡️ https://ow.ly/6AbI50Yy7w6

📌 First meta-analysis on recompensation in decompensated cirrhosis 🔍 More common in viral etiologies & lower MELD 📉 Linked to lower risk of HCC & death ✅ A meaningful clinical endpoint Read more here: https://ow.ly/tYnJ50YvNUo #LiverTwitter @wong__yujun @BavenoCoop

🌟A survey of 54,127 participants from 26 countries identified four dietary clusters associated with global IBS prevalence and severity. The findings highlight regional dietary patterns and their association with IBS. @DipeshVasant 🔗: https://ow.ly/6qOf50YvMM0

📱 Can digital health expand #CRC screening? In the BLITZ study, a smartphone‑based FIT showed feasible use and diagnostic performance comparable to lab FITs for advanced neoplasms, supporting it as an adjunct screening option. #CRCAwarenessMonth 🔗: https://ow.ly/HX6E50YvoBt#CRC#CRCAwarenessMonth

🗣️In a survey of 54,127 participants across 26 countries, four dietary clusters linked to global #IBS prevalence and severity were identified. These findings highlight international dietary patterns and their association with IBS. @DipeshVasant 🔗: https://ow.ly/XzPe50YpHsY

📣 Calling all early-career GIs and PhDs! The AGA Journals are now accepting applications for a one-year editorial fellowship program focused on editorial training and leadership development. ⏰ Apply by 04/30/2026 🔗 Details and application: https://ow.ly/fmRZ50YrtyR

🚨#qFibrosis shows 89.2% repeatability (κ=0.88) and 86.5% reproducibility (κ=0.85) in liver fibrosis scoring, matching human pathologist agreement. The AI platform addresses variability in MASH trials, enabling standardized histological assessment. 🔗:https://ow.ly/miua50YpGRV

📱 Can digital health expand #CRC screening? In this BLITZ study, a smartphone‑based FIT showed feasible use and diagnostic performance comparable to lab FITs for advanced neoplasms, supporting it as an adjunct screening option. #CRCAwarenessMonth 🔗: https://ow.ly/siEs50YqpuP#CRC

🌟Which therapies improve survival in severe alcohol‑associated hepatitis? A new systematic review highlights corticosteroids as first‑line treatment and evaluates emerging combination strategies. 🔗: https://ow.ly/kuog50YpGJq

✴️The March issue of #CGH is now online! This issue includes: 🔸A study on the effect of weight loss on patients with Gastrointestinal & Liver Disease 🔸A review on wearable technologies in #IBD 🔸Research on neoplasia detection rates 🔸...And more! 🔗: https://ow.ly/HeGe50Ym6VX#CGH#IBD

🌟CVE provides a means for automated ulceration and mucosal injury quantitation that shows conceptual agreement with SES-CD. CVE offers new capabilities to improve the granularity and personalization of endoscopic disease assessment in CD. 🔗: https://ow.ly/kmpw50YhhoM

A growing body of evidence suggests microplastics & nanoplastics may affect GI and liver health. A comprehensive @AGA_CGH review found microplastics linked with inflammation, gut dysbiosis, liver disease and possibly GI cancers ➡️ https://ow.ly/j41w50YhkmU @dutta_priyata @AGA_GIHN

‼️New data show acne is a common and impactful side effect of JAK inhibitors in IBD—highlighting the need for early recognition and proactive management. 🔗: https://ow.ly/szta50YhgEN @Sash_Honap @PeyrinBiroulet @ibdseb @eathar_s @shahidadin1 @TakuKobayashiM1 P7278 @PolychronisP

🧬“Distal eosinophilia predicts PPI response in EoE, while proximal‑predominant patterns predict nonresponse. Distribution may reflect distinct phenotypes and guide care.” @walterchanmd @mayssanmuftah 🔗: https://ow.ly/tHtp50Y8M0J

🗣️"Patients with both adenomas and significant serrated polyps face a higher risk of advanced neoplasia than those with either alone. They may benefit from shorter colonoscopy surveillance intervals than current guidelines recommend." 🔗: https://ow.ly/UMmf50Y8Lig

🛎️"Dynamic FIB-4 changes are linked to liver fibrosis progression and adverse outcomes in MASLD. Regular monitoring may support early risk detection and management." 🔗: https://ow.ly/k6vc50Y8KKB

✅"Global cohort of inpt #cirrhosis with external validation showing bili, INR cutoffs for defining liver failure & important impact of #infections & #HE" 🔗: https://ow.ly/tbFM50Y8KBH

🗣️New research found pediatric-specific cutoffs for the fatty liver index and hepatic steatosis index to help diagnose MASLD. These markers may improve early detection and risk stratification of MASLD in youth 🔗: https://ow.ly/PVG850Y52aZ

💡NILDAs are effective alternatives to liver biopsy for fibrosis assessment in MASLD and may serve as a tool to identify patients who are candidates for newer therapies. @RichSterlingMD 🔗: https://ow.ly/LIr950Y51kR

🚨 The newest issue of #CGH is now available! Check it out! 🔗: https://ow.ly/Eu5T50Y4WyG

‼️This new #CGH article observed HCC incidence rates declined and mortality plateaued in the US! 📰 Check out the press coverage: https://ow.ly/2JsR50Y0RpM 📝 Read the article: https://ow.ly/wQEr50Y0RpN

🛎️AMR is rising in patients with cirrhosis. Multidisciplinary effort is crucial to combat AMR and manage bacterial infections in cirrhosis. 🔗 Read More: https://ow.ly/aMJS50Y0Ep0

🧬Etrasimod shows strong induction & maintenance efficacy in moderate–severe endoscopic UC, with potential continued improvement beyond 12 weeks—promising news for patients and clinicians. 🔗 Read more:https://ow.ly/YcVz50Y0Efj

💠New #CGH article on Night-shift workers showing a strikingly high prevalence of IBS and functional dyspepsia. 📰 Check out the press coverage: https://ow.ly/MGJI50Y0R8z 📝 Read the article: https://ow.ly/EqzV50Y0R8A#CGH

💠New #CGH article on Night-shift workers showing a strikingly high prevalence of IBS and functional dyspepsia. 📰 Check out the press coverage: https://ow.ly/tWJb50Y0R3r 📝 Read the article: https://ow.ly/q8OS50Y0R3q#CGH

📱Among 654 participants offered both tests, 55% used the smartphone FIT (76% valid) and 98% used the lab FIT. Overall, 89% found the smartphone test useful. Main reasons for not using it were technical issues or general concerns. Sensitivity matched the lab FIT. 🔗: https://ow.ly/2N3B50XWI7H

💭nCPAP reduces hypoxia risk and stabilizes O₂ levels in patients with obesity during sedated upper GI endoscopy, supporting its routine use in high‑risk patients. More studies should explore wider clinical use. 🔗: https://ow.ly/K83M50XWHN3